- Illumina, headquartered in San Diego, California, is a leader in genomics and biotechnology, specializing in next-generation sequencing (NGS) and array-based solutions for genetic analysis, with a strong market position in precision medicine and oncology.
- In January 2026, Illumina completed the acquisition of SomaLogic, enhancing its multiomics capabilities and expanding its offerings in proteomics, and also launched the TruPath Genome and DRAGEN v4.5 software to improve genomic insights and reduce false positives in cancer samples.
- Key partnerships include collaborations with AstraZeneca, Merck, and Eli Lilly for the Billion Cell Atlas project, aimed at accelerating AI and drug discovery, while their TruSight Oncology Comprehensive test has secured CMS reimbursement to enhance access to precision oncology.
- Illumina's ideal buyers are healthcare providers and pharmaceutical companies looking to leverage advanced genomic profiling and multiomics solutions to solve challenges in personalized medicine and drug discovery, making their offerings increasingly relevant in the evolving healthcare landscape.
Illumina's workforce is organized into 19 departments, with the largest being Information Technology at 898 employees, followed by Community and Social Services with 723 employees. Operations also plays a significant role, housing 674 employees. This diverse departmental structure indicates a balanced focus on both technical and support functions, essential for the company's operational efficiency and community engagement.
The company operates across 229 locations, with a significant concentration in San Diego, CA, which employs 2,287 individuals. Other notable locations include Hayward, CA, with 91 employees, and Madison, WI, with 58. The 'Other' category, comprising 1,999 employees, suggests a distributed workforce that may include remote positions, contributing to a geographically diverse operational footprint.
